#Pharma

Articles tagged with "Pharma"

13 articles found

Semaglutide and the GLP-1 Wave: The Investment Thesis Behind Pharma's Biggest Boom

A deep dive into semaglutide (Ozempic, Wegovy) for investors: what it is, the problem it solves, how Novo Nordisk built a $30bn franchise, the Lilly duopoly, and which Indian companies stand to win as the patent expires.

Drug Patents, Generic Moats, and India's Global Edge in Generic Medicines

How 20-year drug patents create billion-dollar moats, why Indian generics companies broke that system, and what patent cliffs mean for investors.

AI, Protein Folding, and the Future of Drug Discovery: What Investors Should Know

How AI cracked the 50-year protein-folding problem, why it's reshaping drug discovery, and an investor's map of the companies at the frontier — with a clear-eyed view of the risks.

Biosimilars Explained: The Investment Thesis Behind Pharma's Next Big Wave

Biosimilars explained for investors: how they differ from generics, the US$300bn patent cliff, and which Indian companies stand to win.

How to Evaluate a Pharma Stock: The Complete Investor's Guide

The 12 metrics every investor must check before buying a pharma stock, explained simply with Indian examples from Sun Pharma, Cipla, and Dr. Reddy's.

Biologics Explained: The Living-Cell Medicines Reshaping Pharma

A beginner-friendly, investor-first guide to biologics: what they are, how they're made in living cells, why they're so expensive and hard to copy, and why that matters for pharma investors.

Mankind Pharma: The Disruptor That Built India's Largest Field Force

A deep dive into Mankind Pharma's business: how a Delhi-based company cracked Tier 2/3 India, built the Manforce and Gas-O-Fast brands, and what its premium valuation means for investors.

Sun Pharma Stock Analysis: Business Model, Moat, and Investment Case

A complete Sun Pharma analysis for beginners: how the business makes money, its branded pharma moat, the Ranbaxy story, and an honest bull and bear case.

From Lab to Pharmacy: How India's Drug Industry Really Works

A beginner's guide to India's pharma value chain: from drug discovery to patient, every stakeholder, business, and investment opportunity explained.

Natco Pharma: A Long-Term Investor's Honest Assessment at ₹883

A deep-dive analysis of Natco Pharma using all 12 pharma-specific metrics — revenue mix, FDA compliance, Para IV pipeline, return ratios, and valuation — at a time when the stock sits 28% off its 52-week high.

The FDA's Naughty List: What Indian Pharma Investors Need to Know

Warning letters, import alerts, and consent decrees — a complete guide to US FDA enforcement actions against Indian pharma companies, with case studies on Ranbaxy, Sun Pharma, Cipla, Lupin and more.

Cipla: Affordable Medicines, Global Reach, and a 90-Year Moat

A deep dive into Cipla's business: the 1935 founding, the HIV drug story that changed global pharma, its respiratory franchise, and honest bull and bear cases.

Dr. Reddy's Laboratories: The Export-Led Generic Powerhouse

A deep dive into Dr. Reddy's business: how India's most export-focused pharma company built its US generics empire, its Russia franchise, and what the biosimilar bet means.

Ambika Iyer

June 10, 2026

18 min read